Oxford BioSignals Receives FDA Approval For BioSign(TM) Technology

Published: May 08, 2006

INDIANAPOLIS--(BUSINESS WIRE)--May 8, 2006--Oxford BioSignals announced today that the Food and Drug Administration has approved its 510(k) application to market BioSign(TM) in the United States. BioSign, an accessory device to multi-parameter patient monitors, analyzes five vital signs and assigns a Patient Status Index(TM) which continuously represents how different a patient's vital signs are with respect to normal patient conditions. BioSign is intended to help health care professionals and Rapid Response Teams identify patients in crisis and intervene earlier to correct the problem. Earlier intervention is expected to lead to reduced code calls and lower mortality within the hospital.

Back to news